We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+4.24%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.94B
AUM Growth
-$224M
Cap. Flow
-$1.92B
Cap. Flow %
-24.14%
Top 10 Hldgs %
74.98%
Holding
115
New
11
Increased
21
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$30.4M
2
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$19.4M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$16.5M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$15.8M
5
XNPT
XENOPORT, INC.
XNPT
+$13.6M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$209M
2
QCOR
QUESTCOR PHARMA INC
QCOR
+$46.2M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$32.8M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.1M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 39.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
26
TG Therapeutics
TGTX
$8.19B
$21.9M 0.28%
2,050,313
-110,652
-5% -$1.03M
HRTX icon
27
Heron Therapeutics
HRTX
$93.4M
$21.7M 0.27%
2,607,784
– –
MNK
28
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$18.2M 0.23%
+201,856
New +$15.8M
ARWR icon
29
Arrowhead Research
ARWR
$12.1B
$18.2M 0.23%
1,230,802
-200,000
-14% -$2.73M
AMBI
30
DELISTED
Ambit Biosciences Corp
AMBI
$16.8M 0.21%
1,093,332
+345,378
+46% +$2.37M
INSM icon
31
Insmed
INSM
$22.4B
$14.5M 0.18%
1,107,850
+803,800
+264% +$12.1M
AGIO icon
32
Agios Pharmaceuticals
AGIO
$2.08B
$10.4M 0.13%
169,893
-30,000
-15% -$1.29M
OMER icon
33
Omeros
OMER
$845M
$10.3M 0.13%
808,775
+54,971
+7% +$770K
ABUS icon
34
Arbutus Biopharma
ABUS
$847M
$10.2M 0.13%
484,156
– –
KYTH
35
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$10.2M 0.13%
311,255
– –
SGMO
36
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.33M 0.12%
864,856
+342,092
+65% +$4.47M
NBIX icon
37
Neurocrine Biosciences
NBIX
$18.2B
$8.69M 0.11%
554,590
– –
RARE icon
38
Ultragenyx Pharmaceutical
RARE
$2.46B
$8.49M 0.11%
150,000
+50,000
+50% +$2.52M
NGNE icon
39
Neurogene
NGNE
$672M
$8.07M 0.1%
60,593
– –
MTEM
40
DELISTED
Molecular Templates, Inc.
MTEM
$7.79M 0.1%
13,080
+2,011
+18% +$1.39M
QLTI
41
DELISTED
QLT Inc
QLTI
$6.94M 0.09%
1,535,863
– –
PRQR icon
42
ProQR Therapeutics
PRQR
$244M
$6.88M 0.09%
+400,000
New +$6.41M
WINT
43
DELISTED
Windtree Therapeutics Inc
WINT
$6.72M 0.08%
260,866
– –
MGNX icon
44
MacroGenics
MGNX
$233M
$6.52M 0.08%
311,891
– –
OSIR
45
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$6.43M 0.08%
510,606
– –
AERI
46
DELISTED
Aerie Pharmaceuticals
AERI
$6.19M 0.08%
299,356
– –
EPZM
47
DELISTED
Epizyme, Inc
EPZM
$5.8M 0.07%
214,012
– –
CNCE
48
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$5.69M 0.07%
451,496
+52,696
+13% +$511K
FOMX
49
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.57M 0.07%
+1,021,600
New +$5.87M
BLUE
50
DELISTED
bluebird bio
BLUE
$5.38M 0.07%
11,580
-3,726
-24% -$1.72M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2014 Portfolio in Review

As of Q3 2014, Baker Bros. Advisors held 115 positions worth $7.94B, down 2.7% from $8.16B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Baker Bros. Advisors withdrew a net $1.92B in Q3 2014, closing 7 positions and reducing 12 holdings. Its most notable exit was INTERMUNE INC, an estimated $209M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 40% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in MALLINCKRODT PUBLIC LIMITED COMPANY worth $18.2M.

  • Baker Bros. Advisors's largest Q3 2014 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 201,856 shares worth $18.2M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q3 2014, an estimated $30.4M increase.
  • Baker Bros. Advisors's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $18.1M.
  • Baker Bros. Advisors fully exited INTERMUNE INC in Q3 2014, selling an estimated $209M.
  • Baker Bros. Advisors's ten largest holdings make up 75% of its $7.94B portfolio in Q3 2014.
  • Baker Bros. Advisors opened 11 new positions and closed 7 in Q3 2014.
  • Baker Bros. Advisors's portfolio value fell 2.7% quarter-over-quarter to $7.94B.

Based on Baker Bros. Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.